For Non-Small Cell Lung Cancer, Nintedanib Improves Overall Survival Without Reducing Quality of Life
the Cancer Therapy Advisor take:
According to a new analysis published in the European Journal of Cancer, researchers have found that second-line nintedanib plus docetaxel for the treatment of patients with advanced non-small cell lung cancer (NSCLC) improves overall survival without decreasing quality of life.
In the double-blind, placebo-controlled, phase 3 LUME-Lung 1 study, researchers found that the combination of nintedanib with docetaxel significantly improved overall survival when used as second-line treatment for patients with advanced NSCLC and adenocarcinoma histology.
Now, researchers assessed whether the combination therapy affected patient-reported outcomes for symptoms and health-related quality of life. Patients were asked about their symptoms at screening, on the first day of each cycle, at the end of chemotherapy, and at the first follow-up appointment.
Results showed that there was no significant difference in time to deterioration of quality of life or lung cancer-specific symptoms, such as cough, dyspena, and pain, between both arms.
The difference was similar for both the overall population and those with adenocarcinoma. However, the time to deterioration of certain gastrointestinal symptoms was shorter in the nintedanib arm compared with the placebo arm. There was also no significant difference in the EuroQol disease-generic questionnaire between the two treatment arms.
Nintedanib plus docetaxel for the treatment of advanced NSCLC improves overall survival without decreasing quality of life.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer
- Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML
- Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma